Dasatinib Dosing Guidelines

Dasatinib (Dasatinib) is a highly effective oral therapeutic drug, mainly targeting patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It has a wide range of applications, including newly diagnosed adult CML patients, adult patients with CML and ALL who have responded poorly to or cannot tolerate other treatments, and pediatric patients of specific age groups. However, its safety and effectiveness in children under one year of age require further study.

In terms of dosage, the dosage of dasatinib is adjusted based on the condition and the patient's weight. For chronic phaseCML, the recommended dose is 100 mg daily. For accelerated phase CML, myeloid or lymphoblastic phase CML, and Ph+ ALL, it is recommended that the dose be increased to 140 mg daily. For pediatric patients, the dose is calculated based on body weight. Patients weighing 10-19kg, 20-29kg, 30-44kg and 45kg or above correspond to doses of 40mg, 60mg, 70mg and 100mg respectively. Also, as patients' weight changes, it is recommended that the dose be re-evaluated every three months and adjusted more frequently if necessary.

In terms of taking method, dasatinib tablets can be taken once daily with or without food. It is important that the tablets are not crushed, cut or chewed but should be swallowed whole. For patients or children who are unable to swallow the tablets whole, they should choose the appropriate way of taking them under the guidance of a doctor. Additionally, to protect the skin from direct contact with the medication when handling accidentally crushed or broken tablets, it is recommended to wear latex or nitrile gloves.

In summary, dasatinib, as an effective oral treatment, provides a new treatment option forPh+ CML and ALL patients. During taking, patients should strictly follow the doctor's recommendations and dosage to ensure the best efficacy and safety of the drug.